Introduction {#s1}
============

Lung adenocarcinomas are the most common histological type of non-small cell lung cancer (NSCLC) \[[@C1]\]. Invasive adenocarcinomas consist of a mixture of different histological patterns, termed lepidic, acinar, solid, papillary or micropapillary \[[@C2]\]. Lepidic predominant adenocarcinoma (LPA) is characterised by predominant "lepidic growth", meaning proliferations of bland pneumocyte cells growing along the pre-existing alveolar structure. Compared to other NSCLC types, LPA less frequently affects smokers and there is no sex bias \[[@C3]\]. While LPA is typically a non-mucinous adenocarcinoma, a mucinous variant does exist, termed invasive mucinous adenocarcinoma (IMA) \[[@C2]\]. In IMA, tumoural cells have the morphology of goblet or columnar cells, with abundant intracytoplasmic mucin and small, basally located nuclei; they usually appear as well-differentiated cells. IMA is associated with a worse prognosis than other NSCLC subtypes, probably due to its aerogenous spreading, which accounts for the common multicentric and bilateral lung involvement observed in these cases \[[@C4]--[@C14]\], and the lack of effective treatment at this stage. Patients with IMA usually present with respiratory signs at diagnosis. In cases of relapse following surgery, typically the lungs are exclusively involved, and patients usually die of respiratory failure in advanced-stage disease \[[@C3], [@C14]\].

The molecular mechanisms of LPA and IMA are not yet fully understood. *EGFR* mutations are associated with LPA, whereas *KRAS* mutations and oncogenic fusion genes appear to drive IMA \[[@C14]--[@C19]\].

This study sought to identify the cytokines or chemokines that are differentially expressed in LPA and IMA and their role in tumoural promotion.

Materials and methods {#s2}
=====================

Clinical samples and ethical considerations {#s2a}
-------------------------------------------

Between January 1992 and July 2010, 92 patients with LPA and IMA were diagnosed in our chest department. The diagnosis was reviewed by a lung pathologist (M.A.) based on the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification \[[@C2]\]. Disease stage was classified according to the seventh edition of the international TNM Classification of Malignant Tumours \[[@C20]\]. Follow-up data were recorded until death. Surgical resection was performed in 54 patients, with surgical paraffin-embedded samples available for all 54 patients, and frozen surgical samples for 14 patients.

Bronchoalveolar lavage fluid (BALF) was used as a diagnostic tool, as previously described \[[@C21]\]. Following diagnosis, the remaining BALF was spun and the supernatant aseptically separated and stored at −80°C. Frozen BALF supernatant samples were available for 70 patients. Information about control individuals has been provided in the supplementary methods.

All patients signed a research approval informed consent form. All informed consent forms were collected and stored in the Tenon Pathology Department (*Tumorothèque des Hôpitaux Universitaires de l\'Est Parisien,* Tenon Hospital). This study was approved by our hospital\'s ethics human research committee.

Cell lines and culture conditions {#s2b}
---------------------------------

Human H358, H322, A549, H2228, H441 and H1650 lung adenocarcinoma cell lines and the human lung primary fibroblasts (CCD16-Lu) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and the human lung microvascular endothelial cells (HMVEC-L) from Lonza (Levallois, France). Details of the cell lines and culture conditions have been provided in the supplementary methods. Morphologic, phenotypic and molecular characteristics of the cell lines are summarised in supplementary table S1.

Chemokine and cytokine quantification in bronchoalveolar lavage fluid {#s2c}
---------------------------------------------------------------------

Chemokine and cytokine concentrations in BALF supernatants were quantified using Bio-Plex multiplex bead-based assays by means of Bio-Plex Pro™ Human Cytokine 27-Plex Immunoassay and three individual assays for human VCAM-1, growth regulated protein-α (GRO-α) and hepatocyte growth factor (HGF) (Bio-Rad Laboratories, Marnes-la-Coquette, France). For each cytokine calibration curve, eight standards were used. Data acquisition and analysis were completed using the Bio-Plex® 200 System with workstation Bio-Plex Manager™ software Version 5.0 (Bio-Rad Laboratories). Each condition was performed in duplicate.

Immunohistochemistry {#s2d}
--------------------

Formalin-fixed, paraffin-embedded 3-µm tissue sections from surgical specimens were used for C-X-C motif chemokine 10 (CXCL10) and C-X-C motif chemokine receptor 3 (CXCR3) immunohistochemical (IHC) studies. The details of the IHC protocol have been provided in the supplementary methods.

EGFR and KRAS gene mutations and ALK rearrangement analysis {#s2e}
-----------------------------------------------------------

For each formalin-fixed, paraffin-embedded specimen, a 3-μm tissue section was stained with hematoxylin and eosin and examined by light microscopy to determine the presence of tumour cells. After isolating the DNA (QIAamp DNA mini kit, Qiagen, Courtaboeuf, France) from three 20-μm tissue sections, *EGFR* 18--21 and *KRAS* 2 exons were amplified and sequenced in both directions, as previously described \[[@C22]\]. Sequenced data were then analysed using SeqScape software. Immunostaining of the ALK fusion protein was performed on 3-μm tissue sections and processed by a Benchmark Ventana staining module (Ventana Medical Systems, Roche Diagnostics, Meylan, France) using the primary monoclonal antibody against ALK (Clone 5A4, Ab 17127; Abcam, Paris, France) diluted at 1:50 for 2 h at 37°C, as previously described \[[@C23]\]. A positive external control was performed, using an adenocarcinoma specimen that had been previously validated for *ALK* rearrangement by fluorescent *in situ* hybridisation (FISH). The percentage of positive cells was evaluated and staining scores were assessed as follows: 0, no staining; 1+, faint cytoplasmic staining; 2+, moderate cytoplasmic staining; and 3+, intense granular cytoplasmic staining. The presence of 10% of cells stained with an intensity of ≥2 was considered as positive staining. Specimens with a positive score were tested for *ALK* rearrangement by FISH. Briefly, FISH was performed on unstained 4-μm formalin-fixed, paraffin-embedded tumour-tissue sections using an *ALK* break-apart probe set (Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe; Abbott Molecular, Rungis, France) and a paraffin-pretreated reagent kit (Vysis, Abbott Molecular) according to the manufacturer\'s instructions. Tumour tissues were considered *ALK*-FISH positive if \>15% of the cells showed split red and green signals and/or single red signals.

RNA and quantitative reverse transcriptase PCR {#s2f}
----------------------------------------------

The details of the quantitative reverse transcriptase (qRT)-PCR protocol have been provided in the supplementary methods.

Western blotting analysis {#s2g}
-------------------------

The details of western blotting protocol have been provided in the supplementary methods.

ELISA assays {#s2h}
------------

CXCL10 expression was determined in the cell supernatants using ELISA detection kits, in accordance with the manufacturer\'s instructions (R&D Systems, Minneapolis, MS, USA).

Cell migration assay and cell proliferation assay {#s2i}
-------------------------------------------------

The details of the cell migration assay (3-\[4, 5-dimethylthiazol-2-yl\]-2, 5-diphenyltetrazolium bromide (MTT) assay) protocol have been provided in the supplementary methods.

Statistical analysis {#s2j}
--------------------

Our results are expressed as mean±[sem]{.smallcaps}. For quantitative variables, comparisons were made using the Mann--Whitney and Kruskal--Wallis non-parametric tests. For qualitative variables, the Chi-squared test was used for comparisons and Spearman\'s rank correlation coefficient (rho) for correlation analysis. A p-value \<0.05 was considered statistically significant.

Survival time was defined as the time from diagnosis to death or the cut-off date, fixed at August 2011. Survival rates were calculated by means of the Kaplan--Meier method and survival curves compared using the log-rank test. Quantitative variables were coded as dichotomous (present or absent and high or low level), and the cut-off values represented the means of sampling distribution. Multivariate analysis was performed by means of Cox\'s multiple regression models. The lack of co-linearity between variables was verified using the Chi-squared test. Variables with a p-value \<0.1 on univariate analysis were tested in the multivariate Cox model, with the final model chosen using a backward stepwise variable selection process based on the p-value as a candidate predictor. The threshold of significance was set at p\<0.05. All findings were processed using SPSS 20.0 software (IBM Corporation, Armonk, NY, USA).

RESULTS {#s3}
=======

Clinical, pathological and molecular characteristics of the patients {#s3a}
--------------------------------------------------------------------

Clinical and molecular findings are summarised in [table 1](#TB1){ref-type="table"}. Five mixed cases of IMA showing mucinous and non-mucinous patterns were identified in surgical samples. All driver oncogenes detected were mutually exclusive. As shown in [table 2](#TB2){ref-type="table"}, never smokers were more common among patients diagnosed with an IMA (p=0.032) than an LPA. There was no difference in age at diagnosis, sex, performance status at diagnosis and clinical stage according to histological status. *EGFR* mutations were exclusively detected in LPA and there was a trend for a higher proportion of *KRAS*-positive tumours in IMA compared to LPA (30% *versus* 17% of those with available data, p=0.277) ([table 2](#TB2){ref-type="table"}).

###### 

Clinical, pathological and molecular characteristics of the patients

                                                  **Patients**
  ---------------------------------------------- --------------
  **Subjects n**                                       92
  **Age years (mean±[sem)]{.smallcaps}**              65±1
  **Sex**                                        
   Female                                           42 (46)
   Male                                             50 (54)
  **Smoking status**                             
   Never smoked                                     25 (27)
   Former or current                                67 (73)
  **Performance status**                         
   0                                                60 (65)
   \>0                                              30 (33)
   MD                                                2 (3)
  **Histological status**                        
   Invasive mucinous adenocarcinoma                 49 (53)
   Invasive lepidic predominant adenocarcinoma      36 (39)
   Cytological diagnosis                             7 (8)
  **Stage**                                      
   I                                                15 (16)
   II                                               17 (18)
   III                                               7 (8)
   IV                                               53 (58)
  ***EGFR* mutation**                            
   Positive                                          8 (9)
   Negative                                         65 (71)
   MD                                               19 (20)
  ***KRAS* mutation**                            
   Positive                                         18 (20)
   Negative                                         55 (60)
   MD                                               19 (20)
  ***ALK* rearrangement**                        
   Positive                                          1 (1)
   Negative                                         72 (79)
   MD                                               19 (20)

Data are presented as n (%), unless otherwise stated. MD: missing data.

###### 

Clinical and molecular characteristics according to histological status

                                            **Invasive mucinous adenocarcinoma**   **Lepidic predominant adenocarcinoma**   **p-value**
  ---------------------------------------- -------------------------------------- ---------------------------------------- -------------
  **Subjects n**                                             49                                      36                    
  **Age years (mean±[sem]{.smallcaps})**                    65±2                                    64±2                     0.74^\#^
  **Sex**                                                                                                                    0.083^¶^
   Female                                                 19 (39)                                 21 (58)                  
   Male                                                   30 (61)                                 15 (42)                  
  **Smoking status**                                                                                                         0.032^¶^
   Never smoked                                           19 (39)                                  6 (17)                  
   Former or current                                      30 (61)                                 30 (83)                  
  **Performance status**                                                                                                     0.336^¶^
   0                                                      32 (65)                                 27 (75)                  
   \>0                                                    16 (33)                                  8 (22)                  
   MD                                                      1 (2)                                   1 (3)                   
  **Stage**                                                                                                                  0.514^¶^
   I                                                       8 (16)                                 11 (30)                  
   II                                                     12 (24)                                  7 (19)                  
   III                                                     5 (10)                                  3 (8)                   
   IV                                                     24 (50)                                 15 (43)                  
  ***EGFR* mutation**                                                                                                       \<0.001^¶^
   Positive                                                0 (0)                                   8 (22)                  
   Negative                                               44 (90)                                 21 (58)                  
   MD                                                      5 (10)                                  7 (20)                  
  ***KRAS* mutation**                                                                                                      
   Positive                                               13 (27)                                  5 (13)                    0.277^¶^
   Negative                                               31 (63)                                 24 (67)                  
   MD                                                      5 (10)                                  7 (20)                  
  ***ALK* rearrangement**                                                                                                    0.999^¶^
   Positive                                                1 (2)                                   0 (0)                   
   Negative                                               42 (86)                                 30 (83)                  
   MD                                                      6 (12)                                  6 (17)                  

Data are presented as n (%), unless otherwise stated. MD: Missing data. ^\#^: Mann-Whitney test for comparison of the mean; ^¶^: Chi-squared test of general association.

Cytokine expression in bronchoalveolar lavage fluid {#s3b}
---------------------------------------------------

We assessed chemokine and cytokine concentrations in BALF supernatants from patients (n=70) and controls (n=7) by performing multiplex cytokine assays. Of the 30 proteins examined, 10 were present in higher concentrations in patients (CXCL10, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1β (MIP-1β), regulated on activation, normal T cell expressed and secreted (RANTES), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, granulocyte-colony stimulating factor (G-CSF) and interferon-γ (IFNγ)) ([table 3](#TB3){ref-type="table"}). Only CXCL10 was differentially expressed when comparing IMA with LPA ([figure 1A](#F1){ref-type="fig"}). CXCL10 concentration was higher in IMA compared to LPA and controls (9714 pg·mL^−1^±1693 *versus* 3716 pg·mL^−1^±872 *versus* 504 pg·mL±149, respectively; p=0.004).

###### 

Concentrations of chemokines and cytokines in bronchoalveolar lavage supernatant of the patients and controls based on multiplex antibody bead assay

                                           **Patients**     **Controls**    **p-value^\#^**  **IMA**           **LPA**          **p-value^¶^**
  -------------------------------------- ----------------- --------------- ----------------- ----------------- --------------- ----------------
  **Subjects n**                                70                8                          38                25              
  **Chemokines pg·mL^−1^**                                                                                                     
   GRO-α/CXCL1                             793.70±74.10     749.79±210.38       \>0.05                                         
   IP-10/CXCL10                           7974.18±1213.38   504.28±149.80        0.001       9714.73±1693.40   3716±872.05          0.001
   MCP-1/CCL2                              332.81±81.04      26.04±11.36         0.016       369.17±139.31     231.71±66.89         0.431
   MIP-1a/CCL3                               3.25±1.14        2.61±0.81         \>0.05                                         
   MIP-1b/CCL4                              68.40±14.98      10.99±3.58          0.007       58.04±12.83       42.70±12.99          0.214
   RANTES/CCL5                              93.20±17.11      21.22±12.04         0.037       97.87±23.87       84.48±26.90          0.844
   EOTAXIN/CCL11                            36.69±2.80       31.83±1.57         \>0.05                                         
  **Growth factors pg·mL^−1^**                                                                                                 
   bFGF                                         --               --                                                            
   HGF                                     705.37±171.45     67.62±21.90         0.002       666.34±185.62     642.70±368.56        0.577
   VEGF                                   5071.85±1097.98   366.74±98.96         0.025       5824.14±1778.28   3550±1280.30         0.684
  **Interleukins pg·mL^−1^**                                                                                                   
   IL-1b                                     5.62±2.19        3.71±1.16         \>0.05                                         
   IL-1ra                                  196.64±98.19      89.82±54.40        \>0.05                                         
   IL-2                                         --               --                                                            
   IL-4                                      3.86±1.35        3.41±2.92         \>0.05                                         
   IL-5                                      2.41±0.78        1.18±0.64         \>0.05                                         
   IL-6                                     59.44±14.46       2.5±1.07           0.007       50.99±19.29       47.66±17.59          0.800
   IL-7                                     42.38±12.26      27.65±18.27        \>0.05                                         
   IL-8                                    224.86±51.04      29.17±6.82          0.023       167.32±30.52      154.41±49.36         0.140
   IL-9                                     36.00±2.87       27.42±11.12        \>0.05                                         
   IL-10                                     6.12±1.04        5.80±3.99         \>0.05                                         
   IL-12 (p70)                              35.06±5.33       17.65±10.56        \>0.05                                         
   IL-13                                     1.70±0.55        2.63±1.18         \>0.05                                         
   IL-15                                     1.31±0.19        0.76±0.24         \>0.05                                         
   IL-17                                    34.33±4.43       27.60±18.23        \>0.05                                         
  **Other cytokines pg·mL^−1^**                                                                                                
   G-CSF                                    57.23±10.47      11.18±6.56          0.016       39.79±6.44        71.16±22.84          0.474
   GM-CSF                                    9.05±1.47       15.30±5.87         \>0.05                                         
   IFNγ                                     59.82±14.18      18.22±9.99          0.041       133.64±33.58      58.77±16.67          0.100
   TNFα                                         --               --                                                            
   PDGFβ                                    81.66±18.40      27.76±14.53        \>0.05                                         
  **Cell adhesion molecule pg·mL^−1^**                                                                                         
   VCAM-1                                   1173.66±236     292.50±189.04       \>0.05                                         

Data are presented as mean±SEM, unless otherwise stated. The illustrated results are from one experiment and representative of results from three experiments. All values are the means of triplicate samples. -- designates undetectable levels. IMA: invasive mucinous adenocarcinoma; LPA: lepidic predominant adenocarcinoma. ^\#^: comparison of concentrations using the Mann--Whitney test; ^¶^: comparison of concentrations using the Mann--Whitney test. For each occurrence, concentrations in IMA, LPA and control were all significantly different, according to Kruskal--Wallis test.

![CXCL10/CXCR3 overexpression in invasive mucinous adenocarcinoma (IMA). CXCL10 concentration was assessed in 70 bronchoalveolar lavage fluid (BALF) supernatants from patients by an antibody magnetic bead assay (Bioplex® System). Each sample was assessed in duplicate. a) CXCL10 concentrations in BALF supernatants from IMA (n=38), lepidic predominant lung adenocarcinoma (LPA; n=25) and controls (n=7). p-values reflect Kruskal--Wallis test or Mann--Whitney test. Data displayed as means with [sem]{.smallcaps} indicated by whiskers. b) Survival curve of patients with high and low CXCL10 levels in BALF supernatants (log rank test). c) CXCL10 and CXCR3 staining (brown) in IMA and LPA. d) Correlation between CXCL10 and CXCR3 staining scores (Spearman\'s rho test).](00047-2016.01){#F1}

CXCL10 overexpression and survival {#s3c}
----------------------------------

On univariate analysis, a high level of CXCL10 concentration was associated with shorter survival (high *versus* low: 13 *versus* 40 months, p=0.016) ([figure 1B](#F1){ref-type="fig"}), worse performance status (p=0.004), and stage IV disease (p=0.001) (supplementary table S2). On multivariate analysis, only stage IV disease was associated with shorter survival (supplementary table S2).

Expression of CXCL10 and CXCR3 in surgical samples {#s3d}
--------------------------------------------------

We analysed 54 surgical samples from IMA (n=27) or LPA (n=27). Our pathological findings have been outlined in [figure 1C](#F1){ref-type="fig"}, demonstrating that CXCL10 was expressed in the cytoplasm of tumour cells in 42 patients (78%). CXCL10 expression was uncommon in mononuclear stromal cells. CXCL10 was more commonly expressed in IMA (25 out of 27 patients, 93%) than in LPA (17 out of 27 patients, 63%; p=0.009). CXCL10 staining scores were significantly higher in IMA (110±14) than in LPA (24±2; p\<0.001).

CXCR3 was expressed in the cytoplasmic membrane and in the cytoplasm of tumour cells in 24 patients (44%). CXCR3 was more frequently expressed in IMA (20 out of 27 patients, 74%) than in LPA (4 out of 27 patients, 15%; p\<0.001). CXCR3 staining scores were significantly higher in IMA (69±5) than in LPA (17±2; p=0.047).

CXCL10 staining score strongly correlated with CXCR3 staining score (r=0.527, p\<0.001; [figure 1D](#F1){ref-type="fig"}. Concomitant expression of CXCL10 and CXCR3 in surgical samples was significantly more common in IMA than in LPA (66% *versus* 22%, p=0.002). CXCR3-positive tumours exhibited higher concentrations of CXCL10 in the BALF supernatants than those detected in CXCR3-negative tumours (p=0.005, supplementary figure S1). CXCL10 and CXCR3 expression did not notably differ in cases of IMA showing mixed mucinous and non-mucinous patterns as compared to the overall population (data not shown).

We examined the expression of the CXCR3-A and CXCR3-B mRNA splice variants in frozen surgical samples from IMA (n=7) and LPA (n=7) using qRT-PCR. CXCR3-A and CXCR3-B mRNA was detected in all samples. CXCR3-A mRNA was significantly overexpressed in IMA (2691±450) compared to LPA (1227±191; p=0.022) (supplementary figure S2).

Relationship between EGFR and KRAS status and CXCL10/CXCR3 expression {#s3e}
---------------------------------------------------------------------

CXCL10 expression in BALF and surgical samples as well as CXCR3 expression in surgical samples was comparable in *EGFR*-positive or *EGFR*-negative tumours and in *KRAS*-positive or *KRAS*-negative tumours (supplementary figure S3). Neither *EGFR* status nor *KRAS* status was associated with concomitant expression of CXCL10 and CXCR3 in surgical samples (data not shown).

Functional study of CXCL10/CXCR3-A in cell lines {#s3f}
------------------------------------------------

CXCL10 and CXCR3 expression was assessed in mucinous (H2228, H358, H441) and non-mucinous (H322, H1650, A549) lung adenocarcinoma cell lines. As shown in [figure 2](#F2){ref-type="fig"}, lung adenocarcinoma cell lines did not secrete CXCL10 constitutively. Because CXCL10 has been shown to be up-regulated by IFNγ, we exposed the cell lines to recombinant human (rh) IFNγ. This induced a potent CXCL10 secretion from these cells, whether they were mucinous or non-mucinous ([figure 2A](#F2){ref-type="fig"}) \[[@C24]\]. CXCR3 was expressed in all the cell lines at basal state ([figure 2B](#F2){ref-type="fig"}). At basal state, CXCR3-A and CXCR3-B mRNA splice variants were expressed in the cell lines ([figure 3](#F3){ref-type="fig"}). We next analysed whether CXCL10 regulated CXCR3-A and CXCR3-B mRNA expression. After exposure to rhCXCL10 for 24 h at 250 ng·mL^−1^, CXCR3-A mRNA expression was up-regulated in H2228 cells with a 25-fold increased induction compared to basal state, whereas CXCR3-B mRNA expression was not significantly modified ([figure 3](#F3){ref-type="fig"}). The addition of rhCXCL10 did not significantly influence CXCR3-A or CXCR3-B mRNA splice variant expression in other cell lines.

![CXCL10 and CXCR3 are expressed in lung adenocarcinoma cell lines. a) CXCL10 concentrations in cell line supernatants assessed by ELISA, after exposure to recombinant human interferon-γ (IFNγ) (0, 10 or 50 ng·mL^−1^) (Mann--Whitney test). Each sample was assessed in triplicate and results are representative of three independent experiments. Data displayed as means with [sem]{.smallcaps} indicated by whiskers. \*: p\<0.05; \*\*: p\<0.005; difference between stimulated and unstimulated cells. b) Determination of CXCR3 expression by western blotting in cell lines. Representative of three independent experiments performed for each cell line.](00047-2016.02){#F2}

![CXCL10 up-regulates CXCR3-A splice variant expression in the mucinous H2228 cell line. CXCR3-A and CXCR3-B mRNA quantified by quantitative reverse transcriptase PCR in cell lines at basal state and after exposure to CXCL10 (250 ng·mL^−1^) (Mann--Whitney test). a, b) H2228; c, d) H322; e, f) H358; g, h) H441; i, j) A549; k, l) H1650. Each sample was assessed in triplicate and the results are representative of three independent experiments. Data displayed as means with [sem]{.smallcaps} indicated by whiskers. \*: p\<0.005; difference between basal state and unstimulated cells.](00047-2016.03){#F3}

To determine whether CXCL10 affects signalling pathways, cell lines were exposed to rhCXCL10 for 24 h at concentrations ranging from 50 to 250 ng·mL^−1^. As shown by western blotting, rhCXCL10 induced up-regulation of Erk1/2 phosphorylation in H2228, though no effect was observed in the intracellular signalling in other cell lines (supplementary figure S4).

We assayed the ability of CXCL10 to induce H2228 and H322 migration. Cell lines were exposed for 24 or 48 h to different concentrations of rhCXCL10 in a Boyden chamber. The number of migrating cells was then evaluated, revealing that rhCXCL10 induced the migration of H2228, yet not H322, cells in a time- and dose-dependent manner (supplementary figure S5).

CXCL10 did not affect cell growth in either the H2228 or H322 cell lines, as assessed by MTT assay (data not shown).

Discussion {#s4}
==========

Our findings indicate that IMA is characterised by overexpression of CXCL10 and its receptor splice variant CXCR3-A. This could indicate that CXCL10/CXCR3-A act as an autocrine loop in IMA, being involved in the acquisition of pro-migratory capacities.

CXCL10 is a member of the subfamily of IFNγ-inducible non-ELR CXC chemokines and is expressed by a large variety of human cell types \[[@C24]\]. It was initially described as a major chemoattractant for monocytes, activated T cells and natural killer cells. Here, we have proven the existence of tumour expression of CXCL10/CXCR3 in a specific subtype of adenocarcinoma. We have additionally demonstrated that CXCL10 overexpression is linked to poorer survival, suggesting it has a pro-tumoural capacity. Numerous studies have reported the dual role played by CXCL10 and its receptor CXCR3 in malignancy. In several human cancer models, CXCL10/CXCR3 is involved in the anti-tumoural effects of stromal cells, such as angiostatic mechanisms or the recruitment of CXCR3-positive mononuclear cells involved in immune responses \[[@C24]--[@C26]\]. Conversely, a number of recent works have demonstrated that CXCL10/CXCR3 can promote tumour progression in natural killer nasal lymphomas, colorectal cancers, breast cancers or myelomas by stimulating the pro-migratory or pro-metastatic capacities of tumour cells themselves *via* autocrine or paracrine loops \[[@C27]--[@C33]\]. CXCR3 expression in metastatic colorectal cancer cells is known to be up-regulated and associated with worse survival. The CXCL10/CXCR3 axis promotes invasive and metastatic capacities.

The two major splice variants CXCR3-A and CXCR3-B have a biological impact, with CXCR3-A shown to possess pro-tumoural capacities while CXCR3-B leads to the inhibition of DNA synthesis and the apoptosis of tumour cells \[[@C34], [@C35]\]. We found that these splice variants of CXCR3, namely "anti-tumoural" CXCR3-B and "pro-tumoural" CXCR3-A, were differentially expressed in IMA. There was increased expression of CXCR3-A in IMA compared to that in LPA. In addition, following exposure to CXCL10, CXCR3-A expression was up-regulated in the mucinous H2228 cell line, whereas CXCR3-B expression was not modified. We therefore used H2228 as a model of a functional CXCL10/CXCR3-A autocrine loop, and H322 as a negative control. CXCL10/CXCR3-A stimulated cell migration in the mucinous H2228 cell line, yet not in the non-mucinous H322, which primarily expressed CXCR3-B. We suggest that CXCL10/CXCR3-A up-regulation is a specific feature of IMA. We postulate that inhibiting the CXCL10/CXCR3 axis could present a therapeutic opportunity to avoid lung cancer spreading in IMA. AMG487 is a small-molecular-weight antagonist of CXCR3 and has exhibited the potential to inhibit tumour metastasis in murine models of breast cancer and osteosarcoma \[[@C32]\]. Furthermore, several CXCL10 inhibitors are currently subject to clinical investigation in primary biliary cirrhosis and inflammatory diseases \[[@C36], [@C37]\].

Published data in lepidic adenocarcinoma show that *EGFR* activating mutations are restricted to LPA whereas *KRAS* mutations are more common in IMA \[[@C3]\]. The molecular characteristics of our cohort are in line with these data. *KRAS* mutations appear to drive IMA and RAS activation is known to modulate CXCL10 and CXCR3 expression in breast cancer \[[@C38]\]. However, there was a lack of correlation between *EGFR* and *KRAS* status and the expression of CXCL10 and CXCR3 or co-expression of CXCL10 and CXCR3. This suggests that the CXCL10/CXCR3 pathway is not activated by the *EGFR* or *KRAS* driver oncogene. In the studied cell lines, no *KRAS*- or *EGFR*-positive cells showed a significant CXCL10-induced up-regulation of CXCR3-A or CXCR3-B.

One mucinous cell line among the three studied up-regulated CXCR3-A mRNA under the effect of CXCL10. A greater number of cell lines representative of mucinous lepidic adenocarcinomas would have improved the robustness of our conclusion. However, only few lung adenocarcinoma cell lines have been identified as originating from lepidic adenocarcinomas ("bronchioloalveolar") \[[@C39]\]. Furthermore, among the studied cell lines, it cannot be excluded that mucinous differentiation may be lost after *in vitro* passages, thus explaining why the CXCL10/CXCR3-A loop, along with other IMA molecular features, was lost.

Until recently, the CXCR3/CXCL10 axis was considered to exert potent anti-malignancy effects. Our study results were in line with those of a number of other investigations, suggesting this axis has a central role in promoting tumoural capacities depending on CXCR3 splice variant A signalling. Overall, we have hereby provided new insights into the understanding of IMA biology, opening up the possibility of new therapeutic options for this disease known to be frequently multifocal and unresectable at diagnosis.
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